AMX0114 is an investigational antisense oligonucleotide targeting calpain-2, a calcium-activated protease believed to play a role in ALS disease progression. The Food and Drug Administration (FDA) has ...
A recent large study conducted in Sweden has found that long-term exposure to elevated levels of air pollution may increase the risk for the development of motor neuron disease (MND), as well as ...
Add Yahoo as a preferred source to see more of our stories on Google. Eric Dane is opening up and being completely vulnerable with fans in his first video addressing his ALS diagnosis and a new ...
Darin Nakakihara doesn’t remember much from the day changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, and ...
Please provide your email address to receive an email when new articles are posted on . AMX0114 was developed to target calpain-2, a driver of axonal neurodegeneration. A pending clinical trial will ...
- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS - Phase 1 LUMINA trial of AMX0114 underway; early ...
Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...
~ Designation enables an enhanced development path for VTx-002 and underscores its disease-modifying potential in ALS, a universally fatal disease with no cure ~ Milestone follows recent IND clearance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results